{
    "Rank": 749,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT04550910",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "RO1912-30902"
                },
                "Organization": {
                    "OrgFullName": "National Cancer Institute, Egypt",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients",
                "OfficialTitle": "Randomized Clinical Trial Comparing Two Adjuvant Radiotherapy Hypo Fractionation Schedules In The Treatment of Post Mastectomy Breast Cancer Patients",
                "Acronym": "Breastcancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "September 2020",
                "OverallStatus": "Unknown status",
                "LastKnownStatus": "Recruiting",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "January 1, 2020",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "June 1, 2021",
                    "PrimaryCompletionDateType": "Anticipated"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "February 1, 2022",
                    "CompletionDateType": "Anticipated"
                },
                "StudyFirstSubmitDate": "August 18, 2020",
                "StudyFirstSubmitQCDate": "September 15, 2020",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "September 16, 2020",
                    "StudyFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "September 15, 2020",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "September 16, 2020",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Momen Elsayed Hassan, MSc.",
                    "ResponsiblePartyInvestigatorTitle": "Assistant Lecturer of Radiation Oncology",
                    "ResponsiblePartyInvestigatorAffiliation": "National Cancer Institute, Egypt"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "National Cancer Institute, Egypt",
                    "LeadSponsorClass": "OTHER"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes",
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each week) as adjuvant radiotherapy in female patients with breast cancer after mastectomy.",
                "DetailedDescription": "166 patients of breast cancer patients after mastectomy ( 83 patients in each arm ) will be randomize into 2 hypofractionation arms : Arm A: 40 Gy /15 fx / 3 weeks, 5 days per week . Arm B: 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each week.\n\nSimulation:\n\nPatient will be simulated on CT simulator using breast wedge with angle. Serials will be taken every 2 mm from upper neck down to mid abdomen.\n\nContouring:\n\nCTVcw, CTVRNI will be contoured through RTOG guidelines . PTV is added as 0.5 cm all around CTV. Lungs, Heart, brachial plexus, spinal cord, esophageus and thyroid will be contoured as OAR. (www.rtog.org/CoreLab/ContouringAtlases/BreastCancerAtlas.aspx).\n\nD)Dose Constraints:\n\nArm A:\n\nPTV EVAL ( CW) : V90 % \u2265 90 %. - V105 % \u2264 5% - V107%\u2264 3 %. Ipsilateral lung: V20 less than 20-25% - V 8 less than 35%- Contra lateral lung: V4 less 10 %. Heart: V16 less than 5% (Lt sided). V20 less than 5% (Lt sided). V16 is 0%.(Rt sided) V20 is 0% (Rt sided). Mean heart dose \u2264 320-400 cGy. Contra lateral breast : D max\u2264 240 cGy. V 144 cGy less than 5 %. SCV : V90 % \u2265 90 %. Thyroid : Mean dose less than 35 Gy - V30 less than 50 %.\n\nArm B:\n\nPTV EVAL ( CW) : V90 %\u2265 90 %. - V105 %\u2264 5% - V107%\u2264 2 %.\n\nIpsilateral lung: V30%less than 15 -20% - V15% less than 30-35% - V5 % less than 50-55%.\n\nContra lateral lung : V5 % less than 5%. Heart :V25 % less than 5 % - V5 % less than 30 - 35 %. Contra lateral breast: V3 % less than 5 %. SCV : V90 % \u2265 90 %.\n\nFollow up:\n\nA)Weekly follow up will be done during sessions then regular clinical exam every 3 months to assess :\n\nAcute and late toxicity regarding pain, pulmonary toxicity, dysphagia, skin toxicity and lymphedema.Assessment will be done according to RTOG and CTCv.5.\nAny local (chest wall) recurrence, regional (nodal) recurrence.\n\nB)Annual Mammogram. C)Any another investigation (once indicated)"
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Radiotherapy Side Effect",
                        "Locoregional Recurrence"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Post Op radiotherapy",
                        "Mastectomy",
                        "Locoregional Control"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Not Applicable"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Randomized",
                    "DesignInterventionModel": "Parallel Assignment",
                    "DesignPrimaryPurpose": "Other",
                    "DesignMaskingInfo": {
                        "DesignMasking": "Double",
                        "DesignWhoMaskedList": {
                            "DesignWhoMasked": [
                                "Care Provider",
                                "Investigator"
                            ]
                        }
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "166",
                    "EnrollmentType": "Anticipated"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Arm A",
                            "ArmGroupType": "Other",
                            "ArmGroupDescription": "40 Gy /15 fx / 3 weeks, 5 days per week, is a dose prescribed (after randomization ) for Breast Cancer patients indicated for adjuvant RTH after mastectomy",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Radiation: Hypofractionation Schedules for Breast Cancer patients after mastecomy"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "Arm B",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy is a dose prescribed (after randomization )for Breast Cancer patients indicated for adjuvant RTH after mastectomy",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Radiation: Hypofractionation Schedules for Breast Cancer patients after mastecomy"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Radiation",
                            "InterventionName": "Hypofractionation Schedules for Breast Cancer patients after mastecomy",
                            "InterventionDescription": "Two Radiotherapy HypoFractionation Schedules will be applied, after randomization, for female breast cancer patients after mastectomy.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Arm A",
                                    "Arm B"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Chest wall pain",
                            "PrimaryOutcomeDescription": "Grades of toxicity will be assessed according to The Radiation Therapy Oncology Group (RTOG) morbidity scoring criteria. Scoring starts with low grade toxicity sacle ( Grade 1 or 2) while Grade 3 or 4 considered High grade toxicity.",
                            "PrimaryOutcomeTimeFrame": "3 months form starting of Adjuvant radiotherapy to chest wall."
                        },
                        {
                            "PrimaryOutcomeMeasure": "Dysphagia",
                            "PrimaryOutcomeDescription": "Grades of toxicity will be assessed according to The Radiation Therapy Oncology Group (RTOG) morbidity scoring criteria. Scoring starts with low grade toxicity sacle ( Grade 1 or 2) while Grade 3 or 4 considered High grade toxicity.",
                            "PrimaryOutcomeTimeFrame": "3 months form starting Adj radiotherapy to chest wall."
                        },
                        {
                            "PrimaryOutcomeMeasure": "Skin",
                            "PrimaryOutcomeDescription": "Grades of toxicity will be assessed according to The Radiation Therapy Oncology Group (RTOG) morbidity scoring criteria. Scoring starts with low grade toxicity sacle ( Grade 1 or 2) while Grade 3 or 4 considered High grade toxicity.",
                            "PrimaryOutcomeTimeFrame": "3 months form staring adjvant radiotherapy to chest wal."
                        },
                        {
                            "PrimaryOutcomeMeasure": "Pulmonary Toxicity",
                            "PrimaryOutcomeDescription": "Grades of toxicity will be assessed according to The Radiation Therapy Oncology Group (RTOG) morbidity scoring criteria. Scoring starts with low grade toxicity sacle ( Grade 1 or 2) while Grade 3 or 4 considered High grade toxicity.",
                            "PrimaryOutcomeTimeFrame": "Assessment will be started 6 months after end of adjuvant radiotherapy to chest wall then Biannaully for 2 years."
                        },
                        {
                            "PrimaryOutcomeMeasure": "Brachial plexopathy",
                            "PrimaryOutcomeDescription": "Grades of toxicity will be assessed according to The Radiation Therapy Oncology Group (RTOG) morbidity scoring criteria. Scoring starts with low grade toxicity sacle ( Grade 1 or 2) while Grade 3 or 4 considered High grade toxicity.",
                            "PrimaryOutcomeTimeFrame": "Assessment will be started 6 months after end of adjuvant radiotherapy to chest wall then Biannaully for 2 years."
                        },
                        {
                            "PrimaryOutcomeMeasure": "Lymphedema",
                            "PrimaryOutcomeDescription": "Common Toxicity Criteria v.5 ( Arm volume at CC.Grading done according to Interlimb Volume Difference.Interlimb volume difference > 30 % is considered Grade 3 Lymphedema) and Cheng scale ( To detect proportion of patients having moderate or severe lymphedema (Grade \u300bII)",
                            "PrimaryOutcomeTimeFrame": "Assessment will be started 6 montha form ending adjuvant radiotherapy to chest wall and axilla then then Biannaully for 2 years."
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Local control",
                            "SecondaryOutcomeDescription": "Local Recurrence Rate (LCR) including ipsilateral chest wall +/- regional nodal recurrence",
                            "SecondaryOutcomeTimeFrame": "Annually after the end of chest wall irradiation for 2 years. ] must be confirmed by cytological/ histological assessment"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nInvasive carcinoma of the breast.\nComplete microscopic excision of primary tumour and axillary dissection or SLNB .\nFemales with locally advanced breast cancer ( T3/T4 or N + or both ) who are candidate for neoadjvant chemotherapy regardless pathological stage after mastectomy.\nPatients with pathological stage (T3/ T4, +/- N+) or ( N+, any T) after upfront mastectomy.\nAble to comply with follow up.\nWritten informed consent\n\nExclusion Criteria:\n\nPatients do not match with inclusion criteria.\nCollagen vascular disease, specifically systemic lupus, or scleroderma.\nPregnancy or lactation at the time of radiotherapy.",
                "HealthyVolunteers": "No",
                "Gender": "Female",
                "MinimumAge": "18 Years",
                "MaximumAge": "75 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "CentralContactList": {
                    "CentralContact": [
                        {
                            "CentralContactName": "Momen Hassan, MSc.",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "+2001004209003",
                            "CentralContactEMail": "momen_onco@yahoo.com"
                        },
                        {
                            "CentralContactName": "Osama Yousof, MD",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "+20 122 775 2455",
                            "CentralContactEMail": "osama.soliman@nci.cu.edu.eg"
                        }
                    ]
                },
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Osama Yousof, MD",
                            "OverallOfficialAffiliation": "National Cancer Institute, Egypt",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "NCIEGYPT",
                            "LocationStatus": "Recruiting",
                            "LocationCity": "Cairo",
                            "LocationState": "Fom Elkhalig",
                            "LocationZip": "11796",
                            "LocationCountry": "Egypt",
                            "LocationContactList": {
                                "LocationContact": [
                                    {
                                        "LocationContactName": "Momen Hassan, MSc.",
                                        "LocationContactRole": "Contact",
                                        "LocationContactPhone": "+201004209003",
                                        "LocationContactEMail": "momen_onco@yahoo.com"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "SeeAlsoLinkList": {
                    "SeeAlsoLink": [
                        {
                            "SeeAlsoLinkLabel": "FAST Trial Finds Long-Term Side Effects Similar for Once-Weekly and Conventional Breast Radiation Therapies",
                            "SeeAlsoLinkURL": "http://www.ascopost.com/News/59403"
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "No"
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000012008",
                            "ConditionMeshTerm": "Recurrence"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000020969",
                            "ConditionAncestorTerm": "Disease Attributes"
                        },
                        {
                            "ConditionAncestorId": "D000010335",
                            "ConditionAncestorTerm": "Pathologic Processes"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14540",
                            "ConditionBrowseLeafName": "Recurrence",
                            "ConditionBrowseLeafAsFound": "Recurrence",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M22390",
                            "ConditionBrowseLeafName": "Disease Attributes",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        }
                    ]
                }
            }
        }
    }
}